|
목적 : To evaluate the effect of switching to aflibecept from ranibizumab or bevacizumab in choroidal neovascularization.
방법 : A retrospective review was done on subjects with choroidal neovascularization who switched from ranibizumab 0.5 mg and/or bevacizumab 1.25 mg treatment to intravitreal aflibercept 2.0 mg treatment at the Retina Center of Nune Eye Hospital, in Seoul Korea. The data included prior treatment history, best corrected visual acuity, central subfoveal thickness on spectral domain OCT before and after aflibercept injection, and complications.
결과 : A total of 31 eyes with choroidal neovascularization(AMD 23 eyes, idiopathic CNV 6 eyes, and myopic CNV 2 eye) were switched to aflibercept for 2~3 months. All eyes had an average of 15.0±12.6 regular ranibizumab/bevacizumab injections for 23.4±18.2 months. After aflibercept treatment, the best corrected visual acuity changed from 0.55±0.47 LogMAR to 0.51±0.48 LogMAR (p=0.016) and central subfoveal thickness improved from 424±153 ㎛ to 354±178 ㎛ (p=0.026). The treatment was well tolerated with no adverse events reported except in one subject with increased IOP.
결론 : A significant proportion of subjects with choroidal neovascularization and persistent fluid on OCT despite regular ranibizumab 0.5 mg and/or bevacizumab 1.25 mg treatment responded to aflibercept 2.0 mg with anatomical improvements. However, visual acuity did not improve. We presume Aflibercept to be beneficial anatomically, in subjects with choroidal neovascualrization with persistent fluid on ranibizumab and/or bevacizumab.
|